Fluticasone, cutaneous
Generic name
Fluticasone, cutaneous
Brand name
ATC Code
D07AC17
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Inflammatory dermatoses |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Reported are: growth hormone insufficiency and delayed weight gain in children.
The risk of systemic effects with the use of dermatocorticosteroids is greatest with: use under occlusion, use on large areas of skin or skin folds and concomitant use of penetration enhancing drugs.
[SmPC Cutivate)
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
In infants, the nappy can act as the enclosing dressing and thus increase the absorption. In children, inhibition of the adrenal cortex can occur fairly quickly. In addition, the secretion of growth hormone can be suppressed in them. It is therefore recommended that the height and weight should be checked regularly if prolonged use is required. Careful consideration is needed when applied to the eyelids because of the possibility of contaminating the conjunctiva (and the risk of glaucoma simplex or subcapsular cataracts occurring) on the one hand, and the risk of corneal damage due to the continuous rubbing/scratching of untreated eczema on the other.
In infants and children, the skin barrier, which is not yet completely mature, and a larger body surface in relation to body weight can lead to a correspondingly larger amount of topical corticosteroids being absorbed compared to adults. Therefore, systemic toxicity is more likely to occur in infants and children. Fluticasone propionate should be used with caution, i.e. at the lowest possible effective dose.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
CORTICOSTEROIDS, PLAIN
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Corticosteroids, weak (group I) | ||
|---|---|---|
| D07AA02 | ||
| Corticosteroids, moderately potent (group II) | ||
|---|---|---|
| D07AB02 | ||
| Corticosteroids, potent (group III) | ||
|---|---|---|
| D07AC01 | ||
| D07AC03 | ||
| D07AC13 | ||
References
- Krakowski AC, et al, Management of Atopic Dermatitis in the Pediatric Population, Pediatrics, 2008, Vol. 122 No. 4, 812-824
- CBO, Richtlijn Constitutioneel Eczeem, www.cbo.nl, Maart 2015
- NHG, Standaard constitutioneel exceem (M37), www.nhg.nl, augustus 2006
- Dirven-Meijer PC et al, NHG standaard Eczeem, Huisarts Wet , 2014, 57(5), 240-52
- NDVD, Richtlijn Anogenitale Lichen Sclerosus, www.ndvd.nl, 2012
- GlaxoSmithKline BV, SmPC Cutivate creme 0,5 mg/g (RVG 16648) 16-04-202, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
